Arca
Skip to content
Tools
Tools

Progressive supranuclear palsy

Drug research and approvals for progressive supranuclear palsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 34 studies of progressive supranuclear palsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 20 open orphan designations naming it.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 34 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 3

Phase 2 7

Phase 1 or earlier 5

How its trials ended

139 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 16 whose ending is known, 19% met their primary endpoint, 13% missed it and 69% stopped early.

  • Completed, result not reported6144%
  • Ongoing4532%
  • Status unknown1712%
  • Stopped: other or unclear54%
  • Met its primary endpoint32%
  • Stopped: lack of efficacy32%
  • Stopped: funding32%
  • Missed its primary endpoint21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 30, 2020A randomized, participant, investigator and sponsor blinded, placebo- controlled study to evaluate the safety, tolerability and pharmacokinetics of multiple…NIO752Novartis PharmaceuticalsClosed
May 4, 2017A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intravenously administered BMS-986168 in…BMS-986168Bristol-Myers SquibbClosed
Apr 21, 2017Four repeat tauopathy neuroimaging initiative[C-11]PIB / 18F AV-1451 (18F T807)Pet Centre Centre for Addiction and Mental HealthClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 20
Sep 21, 2026RifampinTreatment of progressive supranuclear palsyMedilabo RFP, Inc.Designated
Jul 23, 2026Sodium selenateTreatment of progressive supranuclear palsyMonash UniversityDesignated
Feb 4, 20262'-methoxyethyl antisense gapmer oligonucleotide against…Treatment of progressive supranuclear palsyNovartis Pharmaceuticals CorporationDesignated
Jun 23, 2025A fully human IgG1k anti-programmed death ligand-1 (PD-L1)…Treatment of progressive supranuclear palsy (PSP)ImmunoBrain Checkpoint Inc.Designated
May 1, 2025TertomotideTreatment of progressive supranuclear palsyGemVax & KAEL Co., Ltd.Designated
Jan 5, 2021Izaflortaucipir (proposed INN)Diagnostic for the clinical management of progressive supranuclear palsy.Lantheus Biosciences Ltd.Designated
Dec 21, 2020FasudilTreatment of progressive supranuclear palsyWoolsey Pharmaceuticals, Inc.Designated
Jun 16, 2020Humanized IgG4 S228P monoclonal antibody targeting the cis…Treatment of Progressive supranuclear palsyPinteon Therapeutics Inc.Designated
Jan 28, 2020Di-deuterated linoleic acidTreatment of Progressive Supranuclear PalsyRetrotope, Inc.Designated
Jul 10, 2018Competitive and reversible small molecule inhibitor of the…Treatment of progressive supranuclear palsyFerrer Internacional, S.A.Designated
Nov 1, 20171-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl…A diagnostic for the management of progressive supranuclear palsyAprinoia TherapeuticsDesignated
Sep 5, 2017Recombinant humanized IgG4P monoclonal antibody with…Treatment of progressive supranuclear palsy (PSP)UCB, Inc.Designated
Mar 20, 2017N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H…Treatment of progressive supranuclear palsyAlzprotect sasDesignated
Jul 13, 2016Tolfenamic acidTreatment of progressive supranuclear palsyNasser H. ZawiaDesignated
May 13, 2015Anti-eTau Humanized IgG4 Monoclonal AntibodyTreatment of Progressive Supranuclear PalsyBiogen, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.